Close Menu

NEW YORK — Progenity on Friday priced its planned initial public offering of 6,666,667 shares of its common stock at $15 per share, making the transaction worth $100 million.

The Ann Arbor, Michigan-based molecular diagnostics testing lab has also granted the underwriters of the offering — Piper Sandler, Wells Fargo Securities, Robert W. Baird, Raymond James, and BTIG — a 30-day option to purchase an additional 1,000,000 shares at the offering price, which would raise another $15 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.